EMD Serono, a subsidiary of Merck KGaA, has signed a research agreement with Pfizer and the Broad Institute in Cambridge, MA focused on the genomic profiling of Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) patients. EMD Serono and Pfizer will jointly fund the research project.   The Broad Institute will study clinical samples from SLE and LN patients, applying biochemical and next-generation sequencing technologies, to identify biomarkers to better define target patient population...